Literature DB >> 3904858

Intrauterine growth retardation.

J M Pearce, S Campbell.   

Abstract

The many problems of diagnosing IUGR are compounded by a lack of ability to detect the dysmature infant from the constitutionally small infant even at birth. Antenatal attempts at detecting IUGR must start with the accurate establishment of gestational age. This can be only accomplished by routine early ultrasound measurement of BPD for all pregnant patients. Subsequently, management is aimed at screening out a group at high risk for having a growth-retarded fetus. Clinical means are poor but SFH measurements or a repeat ultrasound in the third trimester can be expected to detect about 85% of IUGR patients. Diagnosis of IUGR is made by detailed measurement of growth parameters on a serial basis. The use of the H/A ratio chart allows the antenatal division of IUGR into asymmetric and symmetric, such that appropriate investigation and management can be undertaken. The study of flow velocity waveforms obtained by pulsed Doppler ultrasound might in the future help to provide a more rational basis for referring patients to intensive antenatal fetal monitoring.

Entities:  

Mesh:

Year:  1985        PMID: 3904858

Source DB:  PubMed          Journal:  Birth Defects Orig Artic Ser        ISSN: 0547-6844


  2 in total

1.  The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation.

Authors:  Tinnakorn Chaiworapongsa; Jimmy Espinoza; Francesca Gotsch; Yeon Mee Kim; Gi Jin Kim; Luis F Goncalves; Samuel Edwin; Juan Pedro Kusanovic; Offer Erez; Nandor Gabor Than; Sonia S Hassan; Roberto Romero
Journal:  J Matern Fetal Neonatal Med       Date:  2008-01

2.  Morbidity during the first year of life in small for gestational age infants.

Authors:  T Vik; L Vatten; T Markestad; G Ahlsten; G Jacobsen; L S Bakketeig
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1996-07       Impact factor: 5.747

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.